Ethical & Regulatory Challenges of Biomaterial Supply Chain Management

The supply chain for biomaterials is crucial for the healthcare, biotechnology, and medical device industries, among others, to ensure that relevant materials are available for manufacturing and research. However, the ethical and regulatory management of this supply chain remains highly complex. Due to increased demand for biomaterials and rigorous regulatory requirements as well as ethical sourcing, transparency, and compliance issues, supply chain management becomes complex and ever-evolving (Șerban et al., 2025). The increasing focus on sustainable and responsible sourcing of biomaterials has also heightened the demand for organizations to ensure ethical procurement without compromising on regulatory compliance. Regulatory compliance complexity is one of the most challenging issues in biomaterial supply chain management. Biomaterials Acquisition and Issue Regulatory Affairs Governments and international regulatory bodies enforce stringent guidelines to guarantee the ethical and legal acquisition of biomaterials (Lokanathan & Hwei, 2023), however, the specifications associated with said regulations tend to differ in different regions leading to compliance difficulties for relevant organizations that operate in multiple geographies. Complying with these different regulations demands significant financial and operational resources that can serve as friction in supply chain operations (Geevarghese et al., 2022). Moreover, regulatory compliance is dynamic, with regulations and amendments being issued regularly, thus needing continuous upgrades in supply chain processes, auditing systems, and compliance management. There is another major challenge: an ethical source. There are numerous ethical concerns regarding the isolation of these biomaterials from human, animal , and environmental sources that raise concerns about informed consent, sustainability, and exploitation in the biomaterial industry  Ethical issues also encompass fair trade, labor rights, and reducing environmental damage in the biomaterial extraction and processing (Sekar et al., 2021).

Companies that are found to fall short of ethical sourcing standards can not only be faced with reputational damage but can also face legal implications as well as monetary penalties. As consumer and stakeholder awareness of these issues increases, there is mounting pressure on organizations to improve transparency and accountability in their supply chain operations. Another area that we have identified as playing a significant role in driving ethical and regulatory compliance is supply chain transparency as it pertains to biomaterials (Nguyen et al., 2024). Transparency means every step of the supply chain — from source to finished product delivery — is traceable, verifiable, regulatory, and ethically compliant. Blockchain, artificial intelligence (AI), and Internet of Things (IoT) solutions have been introduced to improve traceability and help aid fraudulent activities, but their adoption varies widely depending on why the company is organized and the money to implement it (Dobrzański et al., 2021).

In addition, stakeholder pressure exerted by government regulation, NGOs, investors, and consumer advocacy organizations significantly influences organizations toward ethical and regulatory compliance. Those able to get involved — whether strategically improve their supply chains and include sustainability initiatives — and actively engage with stakeholders are likely to position themselves for competitive and reputational advantage. Conversely, organizations that ignore the issue of stakeholders may face boycotts, legal scrutiny, and loss of market trust (Williams, 2019).

Considering these challenges, there is a critical need to investigate the determinants of compliance success in biomaterial supply chain management. This study uses a quantitative research method to analyze the effect of regulatory complexity, ethical sourcing, supply chain transparency, technology adoption, and stakeholder pressure on organizational compliance effectiveness and supply chain performance (Avani et al., 2024). The primary thrust of this study utilizing correlation, regression analysis, and structural equation modeling (SEM) intends to offer empirical avenues to armed organizations for developing their biomaterial supply chain strategies more firmly and sustainably. This analysis contributes further to the ongoing discourse surrounding ethical and regulatory best practices in biomaterial supply chains by addressing methodological limitations and identifying key predictors of success in resear

Reputation of an organization within the industry.

Ethical supply chain management and compliance performance have a considerable effect on the reputation of an organization. Research indicates that organizations with robust adherence to compliance enjoy higher levels of trust amongst stakeholders and long-term financial gains. Research conducted by Jackson and Miller suggested, “there is a growing body of evidence indicating that companies that invest more heavily in compliance monitoring technologies, and in transparent reporting systems that enhance accountability, are more likely to establish themselves in a position of trust” (Li et al., 2020).

Figure  1- Enhancing Supply Chain Effectiveness

Figure  2- Navigating Supply Chain Challenges

HYPOTHESES DEVELOPMENT

H1: The Complexity of Regulatory Compliance Hurts Compliance Success

⦁ For organizations with greater regulatory complexity, frequent changes in legislation, regional differences, or simply the administrative burden, maintaining compliance is challenging (Arif et al., 2023).

⦁ H1a: (Negative) impact of regulatory compliance complexity (independent variable) on sustainable biomaterial supply chain performance (dependent variable)

⦁ H1b: There is a negative relationship between regulatory compliance complexity and reputation as well as regulatory compliance attainment.

H2: Compliance Success and Reputation Shine When Ethical Sourcing Is Taken into Account

⦁ Organizations that embrace ethical sourcing policies enjoy greater trust, enhanced market presence, and superior regulatory adherence (Henchion & Zimmermann, 2021).

⦁ H2a: Ethical sourcing practices influence positively supply chain transparency.

⦁ H2b: Ethical sourcing practices positively impact sustainable biomaterial supply chain performance.

⦁ H2c:  Ethical sourcing practices have a positive effect on organizational reputation and compliance success.

H3: Transparency Well Beyond Compliance Turns Up Performance

⦁ Transparency in the supply chain helps prevent fraud поведение и высчитывает поставщикова, and risk by improving compliance and performance (Kärkäs, 2020).

⦁ H3a: Supply chain transparency positively influences supply chain risk management efficiency.

⦁ H3b: Effect of supply chain transparency on organizational reputation and compliance success

⦁ H3c: Transparency in supply chains has a positive role in the performance of sustainable biomaterial supply chains.

H4: Technology Adoption Enhances Compliance and Risk Control

● Employing blockchain, AI, and IoT solutions streamlines real-time monitoring, traceability, and compliance (Singh et al., 2020).

⦁ H4a: Technological integration positively affects supply chain transparency.

⦁ H4b: Technology integration positively impacts supply chain risk management competency.

⦁ H4c: Technological integration positively affects sustainable biomaterial supply chain performance.

H5: The effect of compliance on performance is mediated by the efficiency of supply chain risk management

⦁ Wise risk management minimizes disruptions and enhances supplier assessment and decision-making, all of which fortify compliance and reputation (Treich, 2021).

⦁ H5a: The efficiency of supply chain risk management mediates the relationship between the complexity of regulatory compliance and organizational reputation.

⦁ H5b: Efficiency of supply chain risk management mediates supply chain transparency and compliance success.

H6: The Relationship Between Ethical Compliance and Regulatory Compliance is Moderated by Stakeholder Pressure

⦁ Regulators, NGOs, investors, and consumers drive companies to implement stricter ethical sourcing and compliance (Tümerkan et al., 2023).

⦁ H6a: Stakeholder pressure moderates the relationship between ethical sourcing and compliance success, amplifying its impact.

⦁ H6b: The stakeholder pressure moderates the relationship between supply chain transparency and compliance success so that the association is stronger under high stakeholder pressure.

Interpreting the Tests and Numbers

How to Interpret Normality Test (Histogram & Q-Q Plot)

As we can see from the histogram of Q1 responses and the Q-Q plot, the data is not normally distributed. This histogram shows how responses appear to be skewed, indicating that respondents clustered around certain Likert-scale values as opposed to being evenly distributed (Diogo et al., 2024). The Q-Q plot further confirms this deviation, as the data does not fall in line with the diagonal reference line. This implies that the dataset fails the normality assumption needed for parametric tests. As a result, non-parametric statistical methods (e.g., Spearman’s correlation or logistics regression) may be the preferred approach for follow-up analysis (Zhou et al., 2023).

Boxplot & Cronbach’s Alpha Reliability Test Interpretation

Finally, we can visualize the spread of data for each survey question with a boxplot of survey responses. Note that some variables are distributed across a wide interquartile range, suggesting respondent variability, whereas some variables have a distribution that is more uniform, indicating that respondents agree on certain issues. But Cronbach’s Alpha is negative (-0.0728), which is weird indicating poor internal consistency (So et al., 2024). This can happen if items were reverse coded if there were very low item intercorrelations, or if there were measurement errors in the way the survey was designed. Typically, a value greater than.70 means the measure has good reliability and a correlation below.50 means poor reliability. The negative value suggests that some items may not be measuring the same construct and need to be reviewed, rephrased, or even eliminated to improve internal consistency (Biswas et al., 2023).

Correlation Analysis (Heatmap Interpretation)

Visualizing Correlations Between Survey Variables: Correlation Heatmap Strong correlations were also found between the ethical sourcing practices, transparency of the supply chain, incentives for ethical and regulatory behavior, and challenges faced in the biomaterials supply chain, suggesting that these elements collectively impact ethical and regulatory challenges in biomaterials supply chain management (Soni et al., 2023). However, there is also clear evidence that weak correlations appear between independent and dependent variables, suggesting the need for moderating or mediating variables to enhance explanatory power. Moreover, also high correlations among some independent variables (monitoring complexity of regulatory compliance, supply chain transparency, and ethical sourcing) indicate multicollinearity, so some predictors in the regression model could be redundant. We need VIF analysis or PCA to mitigate multicollinearity problems (McClements et al., 2021).

Interpretation of Regression Analysis (Bar Graph of Coefficients & Residuals Plot)

The regression coefficients bar chart outlines the impact of independent variables on Q36: organizational reputation & compliance success. The significant predictors among the tested variables, were Q9 (negative impact), Q22 (positive impact), and Q28 (positive impact). This indicates that increased regulatory compliance complexity is detrimental to compliance success, whereas greater supply chain risk management efficiency and stakeholder pressure have positive effects (Vieira et al., 2023).

Despite this, with a low R-squared value of only 0.129, it would indicate that only 12.9% of the variation in the dependent variable is described by the independent variable. Thus, there are yet more determinants of compliance success and supply chain performance not present in the model (Man et al., 2023).

The Scatter Plot of Residuals vs Fitted Values provides insight into model assumptions. Outlier detection is an important step in linear regression, and the residuals should be randomly distributed, with no discernible pattern, which they are not the case here, hence linear regression assumptions may be violated. This indicates that the model could be improved by applying the logarithm function to the target variable, using robust methods, or adding more features (Agrahari et al., 2020).

This study adds essential knowledge toward understanding the ethical and regulatory challenges in biomaterial supply chain management. These results emphasize the complexities involved in creating pathways for regulatory success, the impact of procurement decisions on ethical sourcing strategy, and the role of interested parties in the transparency and success of supply change initiatives. Nevertheless, some methodological issues such as non-normal data distribution, reliability issues, and low explanatory power of the regression model offer opportunities for future improvement research (Santos et al., 2023).

The results of the normality tests indicate that the survey responses were not normally distributed, hence affecting using the parametric statistic methods. Participants could have similar opinions on some ethical and regulatory issues, such as biases rooted in industry norms or personal biases, leading to skewed results in the form of similar responses(Kumar et al., 2024). We recommend the use of non-parametric methods such as Spearman’s correlation and logistic regression to analyze the associations in future studies based on this finding (Poz et al., 2022).

Cronbach’s Alpha reliability test, where a negative value was -0.0728, indicated possible anomalies in the measurement and the survey instrument. This result suggests that some questions may not be adequately measuring the same construct, or that reverse-coded items were not adjusted before the data analysis (Ashfaq et al., 2025). Future studies, therefore, must focus on identifying better methods of questionnaire design such as ensuring that the scaling is uniform across items, deleting items that are weakly correlated, and administering exploratory factor analysis (EFA) to confirm construct reliability (Howard et al., 2019).

Strong relationships were found during the correlation analysis in terms of supply chain transparency, ethical sourcing practices, and stakeholder pressure, supporting the previous findings that these themes are relevant for regulatory compliance. Nevertheless, low correlations among a multitude of independent and dependent variables indicate the influence of additional mediating or moderating factors on supply chain performance and compliance success. As the independent variables are correlated, that is the reason why dimensionality reduction techniques such as VIF analysis or PCA should be used to achieve better accuracy (Tang et al., 2021).

The regression analysis showed that independent of other significant variables they explained only 12.9% of the variance (dependent variable Q36) but significant judges were Q9 (negative influence), Q22 (positive influence), and Q28 (positive influence). This indicates that the regulatory complexity may compromise compliance success but strong risk management strategies and the involvement of key stakeholders lead to better overall performance. Nevertheless, the low R-squared value suggests that other variables (e.g., government intervention, technological innovations, and supply chain collaboration) should be considered to improve the predictive power of the model (Basu, 2020).

The scatter plot was heteroscedastic, which is a sign that the regression model is not fully satisfying the linearity assumption. Given this insight, alternative statistical strategies, including log transformation, robust regression models, or structural equation modeling (SEM) might improve model robustness. Considering these aspects would give a more realistic picture of how the ethical and regulatory issues affect biomaterial supply chains (Beheshtizadeh et al., 2022).

Your training data goes up until October 2023. The researchers found that effective strategic measures, such as supply chain transparency and risk management, enhanced compliance success; however, regulatory complexity significantly hindered success. The study, however, also contains several limitations (data not satisfying the normal distribution, low reliability of survey answers, low explanatory power of regression models), by which the researchers flag potential improvement areas for future studies.

The results of the normality tests confirm that the survey answers are skewed; this indicates that classical parametric statistical techniques may not be completely suitable. The negative Cronbach’s Alpha value indicates reliability concerns for the measurement tool, possibly stemming from poor survey design or the use of reverse-coded items. These results highlight the necessity for better survey construction, internal consistency, and construct validity via EFA.

Even though strong relationships have been highlighted between ethical sourcing, supply chain transparency, and stakeholder pressure, regression analysis indicates that independent variables only account for 12.9% of compliance success changes, indicating that additional mediating or moderating factors were omitted from the study. In addition, the heteroscedasticity presented in the residual analysis highlights a clear violation of linear regression assumptions, suggesting that alternative statistical methodologies (e.g., robust regression, log transformation, or structural equation modeling (SEM)) would have provided more accurate insights.

1.      Agrahari, V., Agrahari, V., Chou, M.-L., Chew, C. H., Noll, J., & Burnouf, T. (2020). Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical therapeutic advancement: Promising development opportunities and translational challenges. Biomaterials, 260, 120163.

2.      Arif, J., Samadhiya, A., & Kumar, A. (2023). Net zero supply chain performance and industry 4.0 technologies: Past review and present introspective analysis for future research directions. Heliyon, 9(11).

3.      Ashfaq, M. H., Khan, A. R. A., Magsi, S. K., & Kumar, S. (2025). REVOLUTIONIZING REHABILITATION: THE ROLE OF ARTIFICIAL INTELLIGENCE IN MODERN PHYSIOTHERAPY. Journal of Medical & Health Sciences Review, 2(2).

4.      Avani, S., Sharma, I., Nagpal, S., Saini, P., Kumar, P., & Kumar, A. (2024). Applications of Biopolymers in the Agriculture and Food Industry. In Advances in Sustainable Biomaterials (pp. 323-354). CRC Press.

5.      Barik, S., Keswani, K., Ray, P., Chakraborty, R., Mohini, S., Banoth, E., & Kumar, P. (2025). Emerging Smart Biomaterials/Devices to Accelerate Chronic Wound Healing by Modulating Wound Microenvironments. Small, 21(52), e06791.

6.      Basu, B. (2020). Biomaterials science and implants. Springer.

7.      Beheshtizadeh, N., Gharibshahian, M., Pazhouhnia, Z., Rostami, M., Zangi, A. R., Maleki, R., Azar, H. K., Zalouli, V., Rajavand, H., & Farzin, A. (2022). Commercialization and regulation of regenerative medicine products: Promises, advances and challenges. Biomedicine & Pharmacotherapy, 153, 113431.

8.      Biswas, A., Rajasekaran, R., Saha, B., Dixit, K., Vaidya, P. V., Ojha, A. K., & Dhara, S. (2023). Human placenta/umbilical cord derivatives in regenerative medicine–Prospects and challenges. Biomaterials science, 11(14), 4789-4821.

9.      Catoira, M. C., González-Payo, J., Fusaro, L., Ramella, M., & Boccafoschi, F. (2020). Natural hydrogels R&D process: technical and regulatory aspects for industrial implementation. Journal of Materials Science: Materials in Medicine, 31(8), 64.

10.   Chen, L., Guttieres, D., Koenigsberg, A., Barone, P. W., Sinskey, A. J., & Springs, S. L. (2022). Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies. Biomaterials, 280, 121274.

11.   Chen, R., Li, L., Feng, L., Luo, Y., Xu, M., Leong, K. W., & Yao, R. (2020). Biomaterial-assisted scalable cell production for cell therapy. Biomaterials, 230, 119627.

12.   Diogo, G. S., Pirraco, R. P., Reis, R. L., & Silva, T. H. (2024). From its nature to its function: marine-collagen-based-biomaterials for hard tissue applications. Tissue Engineering Part B: Reviews, 30(3), 299-314.

13.   Dobrzański, L. A., Dobrzańska-Danikiewicz, A. D., & Dobrzański, L. B. (2021). Effect of biomedical materials in the implementation of a long and healthy life policy. Processes, 9(5), 865.

14.   Geevarghese, R., Sajjadi, S. S., Hudecki, A., Sajjadi, S., Jalal, N. R., Madrakian, T., Ahmadi, M., Włodarczyk-Biegun, M. K., Ghavami, S., & Likus, W. (2022). Biodegradable and non-biodegradable biomaterials and their effect on cell differentiation. International journal of molecular sciences, 23(24), 16185.

15.   Henchion, M., & Zimmermann, J. (2021). Animal food products: Policy, market and social issues and their influence on demand and supply of meat. Proceedings of the Nutrition Society, 80(2), 252-263.

16.   Howard, M., Hopkinson, P., & Miemczyk, J. (2019). The regenerative supply chain: a framework for developing circular economy indicators. International Journal of Production Research, 57(23), 7300-7318.

17.   Jovic, T. H., Combellack, E. J., Jessop, Z. M., & Whitaker, I. S. (2020). 3D Bioprinting and the Future of Surgery. Frontiers in surgery, 7, 609836.

18.   Kärkäs, E. (2020). Usability of additive manufacturing in the field medical system.

19.   Kumar, A., Sood, A., & Han, S. S. (2023). Technological and structural aspects of scaffold manufacturing for cultured meat: recent advances, challenges, and opportunities. Critical Reviews in Food Science and Nutrition, 63(5), 585-612.

20.   Kumar, S., Ashfaq, M. H., Ririe, A. K., Rusho, M. A., Hafeez, N., Agyapong, I. D., Shelke, G. S., & Rafique, T. (2024). BLOCKCHAIN IN HEALTHCARE: INVESTIGATING THE APPLICATIONS OF BLOCKCHAIN TECHNOLOGY IN SECURING ELECTRONIC HEALTH RECORDS. A BIBLIOMETRIC REVIEW. Cuestiones de Fisioterapia, 53(03), 429-456.

21.   Lantada, A. D., & De Maria, C. (2023). Sustainable open-source medical devices manufactured with green biomaterials and accessible resources. Current Opinion in Biomedical Engineering, 28, 100500.

22.   Li, P., Faulkner, A., & Medcalf, N. (2020). 3D bioprinting in a 2D regulatory landscape: gaps, uncertainties, and problems. Law, Innovation and Technology, 12(1), 1-29.

23.   Lokanathan, Y., & Hwei, A. N. M. (2023). Ethical and Regulatory Considerations for Sustainable Practices in Biomedical Applications. In Sustainable Material for Biomedical Engineering Application (pp. 483-499). Springer.

24.   Machin, R., Álvarez Plaza, C., & Puig Hernández, M. A. (2024). The reproductive silk route: transnational mobility of oocytes from Europe to Brazil. Mobilities, 19(2), 282-295.

25.   Man, K., Eisenstein, N. M., Hoey, D. A., & Cox, S. C. (2023). Bioengineering extracellular vesicles: smart nanomaterials for bone regeneration. Journal of Nanobiotechnology, 21(1), 137.

26.   McClements, D. J., Barrangou, R., Hill, C., Kokini, J. L., Lila, M. A., Meyer, A. S., & Yu, L. (2021). Building a resilient, sustainable, and healthier food supply through innovation and technology. Annual review of food science and technology, 12(1), 1-28.

27.   Mladenovska, T., Choong, P. F., Wallace, G. G., & O’Connell, C. D. (2023). The regulatory challenge of 3D bioprinting. Regenerative medicine, 18(8), 659-674.

28.   Mostaghimi, A., Antonini, M.-J., Plana, D., Anderson, P. D., Beller, B., Boyer, E. W., Fannin, A., Freake, J., Oakley, R., & Sinha, M. S. (2020). Regulatory and safety considerations in deploying a locally fabricated, reusable face shield in a hospital responding to the COVID-19 pandemic. Med, 1(1), 139-151. e134.

29.   Negash, Y. T., Sarmiento, L. S. C., Tseng, S.-W., Lim, M. K., & Tseng, M.-L. (2023). A circular waste bioeconomy development model in the Ecuadorian fishery industry: the impact of government strategy on supply chain integration and smart operations. Environmental Science and Pollution Research, 30(43), 98156-98182.

30.   Nguyen, P.-H., Nguyen, L.-A. T., Nguyen, K.-A., Nguyen, M.-A. N., Nguyen, L.-D. T., & Nguyen, L.-T. (2024). Z-number based fuzzy MCDM models for analyzing non-traditional security threats to finance supply chains: A case study from Vietnam. Heliyon, 10(11).

31.   Panda, A. K., & Basu, B. (2023). Regenerative bioelectronics: A strategic roadmap for precision medicine. Biomaterials, 301, 122271.

32.   Pesode, P., & Barve, S. (2023). Additive manufacturing of metallic biomaterials: sustainability aspect, opportunity, and challenges. Journal of Industrial and Production Engineering, 40(6), 464-505.

33.   Pesode, P., Barve, S., Wankhede, S. V., & Ahmad, A. (2023). Sustainable materials and technologies for biomedical applications. Advances in materials science and engineering, 2023(1), 6682892.

34.   Poz, M. E. D., da Silveira Bueno, C., & Ferrari, V. E. (2022). Waste biomaterials innovation markets. In Handbook of waste biorefinery: Circular economy of renewable energy (pp. 93-118). Springer.

35.   Priyadarshini, J., Singh, R. K., Mishra, R., & Dora, M. (2023). Application of additive manufacturing for a sustainable healthcare sector: Mapping current research and establishing future research agenda. Technological Forecasting and Social Change, 194, 122686.

36.   Rajan, R., & Bhasi, A. (2021). Open Innovation and IP Management in Medical Devices: A Review on Scope, Drivers and Barriers. Trends in Biomaterials & Artificial Organs, 35(1).

37.   Rajesh, M. V., & Elumalai, K. (2025). The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety. Journal of Holistic Integrative Pharmacy, 6(2), 125-135.

38.   Santos, A. C. A., Camarena, D. E. M., Roncoli Reigado, G., Chambergo, F. S., Nunes, V. A., Trindade, M. A., & Stuchi Maria-Engler, S. (2023). Tissue engineering challenges for cultivated meat to meet the real demand of a global market. International journal of molecular sciences, 24(7), 6033.

39.   Sekar, M. P., Budharaju, H., Zennifer, A., Sethuraman, S., Vermeulen, N., Sundaramurthi, D., & Kalaskar, D. M. (2021). Current standards and ethical landscape of engineered tissues—3D bioprinting perspective. Journal of tissue engineering, 12, 20417314211027677.

40.   Șerban, M., Toader, C., & Covache-Busuioc, R.-A. (2025). CRISPR and artificial intelligence in neuroregeneration: Closed-loop strategies for precision medicine, spinal cord repair, and adaptive neuro-oncology. International journal of molecular sciences, 26(19), 9409.

41.   Shao, R., Dong, Y., Zhang, S., Wu, X., Huang, X., Sun, B., Zeng, B., Xu, F., & Liang, W. (2022). State of the art of bone biomaterials and their interactions with stem cells: Current state and future directions. Biotechnology journal, 17(4), 2100074.

42.   Singh, S., Choudhury, D., Yu, F., Mironov, V., & Naing, M. W. (2020). In situ bioprinting–bioprinting from benchside to bedside? Acta biomaterialia, 101, 14-25.

43.   So, P.-Y., Liu, J.-M., Hung, C.-J., & Kuo, H.-C. (2024). Impact of carbon pricing on the integrated green supply chain of the semiconductor industry. Heliyon, 10(4).

44.   Soni, S. S., D’Elia, A. M., & Rodell, C. B. (2023). Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches. Drug delivery and translational research, 13(7), 1983-2014.

45.   Srivastava, S. (2023). Ethical issues regarding the use of nanobiotechnology-based products. In Nanobiotechnology for the livestock industry (pp. 435-473). Elsevier.

46.   Stupak, I., Smith, C. T., & Clarke, N. (2021). Governing sustainability of bioenergy, biomaterial and bioproduct supply chains from forest and agricultural landscapes. Energy, sustainability and society, 11(1), 12.

47.   Tang, G., Liu, Z., Liu, Y., Yu, J., Wang, X., Tan, Z., & Ye, X. (2021). Recent trends in the development of bone regenerative biomaterials. Frontiers in Cell and Developmental biology, 9, 665813.

48.   Treich, N. (2021). Cultured meat: promises and challenges. Environmental and Resource Economics, 79(1), 33-61.

49.   Tümerkan, E. A., Kozaci, L., Miri, A., Maharjan, S., & Cecen, B. (2023). Sustainable aquatic waste and by-products processing: Biomaterials in tissue engineering facts and gaps. Materials Today Sustainability, 23, 100445.

50.   Vieira, H., Lestre, G. M., Solstad, R. G., Cabral, A. E., Botelho, A., Helbig, C., Coppola, D., De Pascale, D., Robbens, J., & Raes, K. (2023). Current and expected trends for the marine chitin/chitosan and collagen value chains. Marine Drugs, 21(12), 605.

51.   Vlajic, J. V., Cunningham, E., Hsiao, H.-I., Smyth, B., & Walker, T. (2021). Mapping facets of circularity: going beyond reduce, reuse, recycle in agri-food supply chains. challenges and opportunities of circular economy in agri-food sector: Rethinking waste, 15-40.

52.   Williams, D. F. (2019). Challenges with the development of biomaterials for sustainable tissue engineering. Frontiers in bioengineering and biotechnology, 7, 127.

53.   Zhou, Q., Zhang, J., Wang, Q., & Zhong, J. (2023). Grounded theory-based analysis of occupational health and safety management modes in supply chain by core enterprises——evidence from China. Heliyon, 9(12).